Taking the Myc out of Cancer: Toward Therapeutic Strategies to Directly Inhibit c-Myc
2020
c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
173
References
19
Citations
NaN
KQI